My Cancer Wiki

@mycancerwiki

“In 2005, a man diagnosed with multiple myeloma asked me if he would be alive to watch his daughter graduate from high school in a few months. In 2009, bound to a wheelchair, he watched his daughter graduate from college. The wheelchair had nothing to do with his cancer. The man had fallen down while coaching his youngest son's baseball team.” ― Siddhartha Mukherjee, The Emperor of All Maladies: A Biography of Cancer

Videos

Playlists

Irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer

Palbociclib + endocrine therapy for hormone-positive HER2-negative metastatic breast cancer: 5 cases

Case of Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Prostate Cancer Treatment

Adenocarcinoma transformation to small cell lung cancer with C797S acquire resistance to osimertinib

Capivasertib for AKT1 E17K-Mutated Metastatic including Breast Cancer: NCI-MATCH EAY131-Y

Palbociclib + Endocrine Therapy vs Capecitabine for HR-Positive HER2-Negative Breast Cancer: PEARL

New Targets Explored for Bispecific T-Cell–Engaging Antibodies in Myeloma

Adding Oxaliplatin to Fluoropyrimidine for Stage III Colon Cancer with Microsatellite Instability

FDA approves relugolix for advanced prostate cancer

FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations

Atezolizumab in combination with carboplatin + etoposide for heavily treated small cell lung cancer

Metastatic uveal melanoma showing durable response to ipilimumab and nivolumab combination therapy after experiencing progression on anti-PD-1 therapy alone

Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared by Crizotinib

Case of Combination Cabozantinib + Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC)

Atezolizumab + Carboplatin/Etoposide for Extensive-Stage Small Cell Lung Cancer: IMpower133 Update

First-Line Nivolumab + Ipilimumab in Metastatic Uveal Melanoma

Bemarituzumab + Chemotherapy Improve Outcome in Advance Gastric and Gastroesophageal Junction Cancer

Anti–PD-1 Therapy Dostarlimab for dMMR/MSI-H Gastrointestinal Cancers: Safety and Efficacy Examined

FDA approves crizotinib for pediatric relapsed or refractory systemic anaplastic large cell lymphoma

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

HER2-positive Gastric Cancer with Nodal Metastasis Successfully Resected After Chemo w/ Trastuzumab

Safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis

Impressive response to dual BRAF + MEK inhibition in 2 patients with BRAF mutant cholangiocarcinoma

Patients With Recurrent Glioblastoma and a Very Low Mutation Burden May Respond Best to Immunotherapy

Length of Hospital Stay With Laparoscopic vs Open Gastrectomy for Gastric Cancer

Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA

IDH Inhibitor Ivosidenib Improve Overall Survival in Previously Treated Cholangiocarcinoma: ClarIDHy

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas

FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis